You are here

  • Home
  • Archive
  • Volume 10, Issue 4
  • Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

 

Online download statistics by month:

Online download statistics by month: April 2022 to September 2025

AbstractFullPdf
Apr 202211001134482
May 20229671006326
Jun 2022841872271
Jul 2022851862164
Aug 2022731746153
Sep 2022756764175
Oct 2022767776174
Nov 2022669677168
Dec 2022577577117
Jan 202355055282
Feb 2023523524102
Mar 2023551553128
Apr 2023529532119
May 2023534534122
Jun 2023517518114
Jul 202339139266
Aug 202336836792
Sep 202335736068
Oct 202337837887
Nov 2023402404110
Dec 2023359359106
Jan 2024306308141
Feb 2024398402132
Mar 2024506507217
Apr 2024464464189
May 2024465469161
Jun 2024372372118
Jul 2024402402127
Aug 202428528485
Sep 202421921996
Oct 2024344344138
Nov 2024417419163
Dec 2024414418156
Jan 2025370371146
Feb 2025425427171
Mar 2025376378159
Apr 2025341341136
May 2025440440196
Jun 202523423585
Jul 2025110
Sep 2025110
Total19498196895842